Table 4 Compliance to TAS-102 treatment
Dose reductions | No | % |
|---|---|---|
Ab initio (− 5 mg/m2/dose) | 9 | 19.1 |
During treatment | 29 | 61.7 |
− 5 mg/m2/dose | 12 | |
− 10 mg/m2/dose | 8 | |
− 15 mg/m2/dose | 9 | |
No dose reduction | 9 | 19.1 |
Dose reductions | No | % |
|---|---|---|
Ab initio (− 5 mg/m2/dose) | 9 | 19.1 |
During treatment | 29 | 61.7 |
− 5 mg/m2/dose | 12 | |
− 10 mg/m2/dose | 8 | |
− 15 mg/m2/dose | 9 | |
No dose reduction | 9 | 19.1 |